Researchers in China report that a simple heart ultrasound measure of left ventricular underfilling is a valuable prognostic ...

A study found that pulmonary hypertension often resolves within a year in premature infants with BPD, though many still ...

Pulmonary hypertension (PH) in extremely premature infants — those born before 28 weeks of pregnancy — who also have bronchopulmonary dysplasia (BPD) usually resolves within the first year and does ...

The rare and severe lung disease called pulmonary hypertension (PH) affects the pulmonary arteries, causing high blood pressure. The pulmonary arteries transport the blood from the right heart ...

Although there is no cure yet for pulmonary hypertension (PH), there are a variety of therapies available that can help manage the symptoms of the disease and maintain or improve the quality of life ...

Pulmonary hypertension (PH) is a rare but severe health condition characterized by high blood pressure in the pulmonary arteries. It is diagnosed when the arteries that transport blood from the heart ...

Pulmonary hypertension (PH) is a rare, life-threatening disease that affects the pulmonary arteries, the lungs, and the heart. Patients who suffer from the disease have narrow and obstructed pulmonary ...

Pulmonary hypertension (PH) is a rare but life-threatening lung disorder that damages the vessels responsible for transporting blood from the heart to the lungs, known as the pulmonary arteries. The ...

Pulmonary hypertension (PH) is a rare but life-threatening disease that affects the pulmonary arteries, making them narrow and thick. The vessels, which are responsible for transporting blood from the ...

Pulmonary hypertension (PH) is characterized by high blood pressure, which affects the pulmonary arteries, the vessels that transport blood from the heart to the lungs. Due to the thickened and ...

Pulmonary hypertension is a rare lung disease characterized by increased blood pressure in the pulmonary arteries that eventually makes breathing very difficult. Breathing is the most important thing ...

Two Phase 3 clinical trials are now recruiting participants to test Tenax Therapeutics‘ experimental therapy TNX-103 (oral levosimendan) in people with pulmonary hypertension associated with heart ...